Genmab A/S (CPH:GMAB)
Denmark · Delayed Price · Currency is DKK | Market Cap | 99.40B +17.2% |
| Revenue (ttm) | 25.29B +20.7% |
| Net Income | 5.32B -27.7% |
| EPS | 84.98 -25.8% |
| Shares Out | 61.39M |
| PE Ratio | 19.05 |
| Forward PE | 19.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 90,193 |
| Open | 1,628.50 |
| Previous Close | 1,616.50 |
| Day's Range | 1,609.50 - 1,631.00 |
| 52-Week Range | 1,275.00 - 2,257.00 |
| Beta | 0.68 |
| Analysts | Buy |
| Price Target | 2,313.13 (+42.87%) |
| Earnings Date | Aug 6, 2026 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n... [Read more]
Financial Performance
In 2025, Genmab's revenue was $3.72 billion, an increase of 19.19% compared to the previous year's $3.12 billion. Earnings were $963.00 million, a decrease of -15.00%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for GMAB stock is "Buy." The 12-month stock price target is kr 2,313, which is an increase of 42.87% from the latest price.
News
Genmab announces new data from studies evaluating epcoritamab
Genmab (GMAB) announced new data from two studies evaluating epcoritamab. Results from the Phase 2 EPCORE DLBCL-3 study showed an overall response rate, ORR, of 67% and a complete response…
Genmab Presents Promising Epcoritamab Data In Elderly DLBCL Patients
(RTTNews) - Genmab A/S (GMAB) reported positive findings from two clinical studies evaluating epcoritamab in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who are not eli...
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Media Release COPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE ® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly...
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-l...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; June 11, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 15,894 restricted stock units and 15,494 warrants to em...
Genmab (GMAB) Reports Strong Data from EPCORE FL-1 Trial Analysis
Genmab (GMAB) Reports Strong Data from EPCORE FL-1 Trial Analysis
Genmab Reports Epcoritamab Benefits Across Relapsed Follicular Lymphoma Subgroups
(RTTNews) - Genmab A/S (GMAB) on Thursday presented new subgroup data from the Phase 3 EPCORE FL-1 trial showing that epcoritamab in combination with rituximab and lenalidomide (R2) delivered consiste...
Genmab presents EPCORE FL-1 subgroup data at EHA 2026 Congress
Genmab (GMAB) announced new data from a post-hoc subgroup analysis from the pivotal Phase 3 EPCORE FL-1 trial, evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, in combinatio...
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
Media Release COPENHAGEN, Denmark; June 11, 2026 Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE ® FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and le...
Genmab Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
Genmab A/S (Nasdaq: GMAB) today announced new data from a post-hoc subgroup analysis from the pivotal Phase 3 EPCORE FL-1 trial, evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antib...
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new data from a post-hoc subgroup analysis from the pivotal Phase 3 EPCORE® FL-1 trial, evaluating epcoritamab, a subcut...
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Company Announcement COPENHAGEN, Denmark; May 29, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this...
Genmab assumed with a Buy at Truist
Truist analyst Gregory Renza assumed coverage of Genmab (GMAB) with a Buy rating and a price target of $40, down from $48. The firm is positive on the company’s transition…
Genmab A/S: Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
Twenty-three abstracts will highlight the versatility and strength of Genmab's portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral prese...
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
Media Release COPENHAGEN, Denmark; May 21, 2026 Twenty-three abstracts will highlight the versatility and strength of Genmab's portfolio and pipeline, including data from the comprehensive epcoritamab...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; May 12, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 2,346 shares as a consequence of the exercise of employee warrants. The increase i...
Genmab price target lowered to DKK 2,250 from DKK 2,400 at Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis lowered the firm’s price target on Genmab (GMAB) to DKK 2,250 from DKK 2,400 and keeps a Buy rating on the shares. Published first on…
Genmab (GMAB) Reports Significant Shareholding by Orbis Investment Management
Genmab (GMAB) Reports Significant Shareholding by Orbis Investment Management
Genmab announces 5.08% stake by Orbis Investment
Genmab (GMAB) announces that Orbis Investment Management has informed the company that through shares, as of May 8, it controlled the voting rights to 3,166,357 shares in Genmab, which amounts…
Genmab price target lowered to $33 from $34 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Genmab (GMAB) to $33 from $34 and keeps an Equal Weight rating on the shares.
Genmab reports Q1 operating profit $180M, consensus $172.7M
Reports Q1 revenue $896M, consensus $901.1M. “We made tangible progress in the first quarter as we continue to integrate Merus and advance our late-stage portfolio – EPKINLY, Rina-S and petosemtamab.
Genmab maintains FY26 guidance
Genmab (GMAB) is maintaining its 2026 financial guidance published February 17, the company stated with its Q1 report.
Genmab Earnings Call Transcript: Q1 2026
Q1 2026 saw 25% revenue growth and 23% operating profit growth, led by strong EPKINLY and TIVDAK sales. Rina-S phase III enrollment finished early, supporting accelerated filings, while guidance for 14% revenue growth and substantial profitability in 2026 was reaffirmed.
Genmab Quarterly report: Q1 2026
Genmab has published its Q1 2026 quarterly earnings report on May 7, 2026.
Genmab Earnings release: Q1 2026
Genmab released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.